Can we accurately report PTEN status in advanced colorectal cancer?

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Hocking, Christopher ^a   Hardingham, Jennifer E ^a,b,c   Broadbridge, Vy ^a   Wrin, Joe ^a,b   Townsend, Amanda R ^a,d   Tebbutt, Niall ^e,f   Cooper, John ^g   Ruszkiewicz, Andrew ^g   Lee, Chee ^f,h   Price, Timothy J ^a,d,f  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b Bazil Hetzel Institute   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e AUSTIN HEALTH   (Australia)

^f Australasian Gastro Intestinal Trials Group   (Australia)

^g SA Pathology   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Colorectal; Copy number; Immunohistochemistry; Mutation; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADVANCED CANCER; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION;

COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OBSERVER VARIATION; PTEN PHOSPHOHYDROLASE; SEQUENCE DELETION; SINGLE-BLIND METHOD; TUMOR MARKERS, BIOLOGICAL;

EID: 84896736808     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-128     Document Type: Article

References (44)

1. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27(22):3677-3683. 10.1200/JCO.2008.20.5278, 2720081, 19470929.
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Change DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(10):1626-1634. 10.1200/JCO.2007.14.7116, 18316791.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shephard L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359(17):1757-1765. 10.1056/NEJMoa0804385, 18946061.
4. Cancer incidence in five continents. IARC Sci Publ 1987, Volume V(88):1-970.
5. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369(11):1023-1034. 10.1056/NEJMoa1305275, 24024839.
6. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, Andre T, Wiezorek J, Reese D, Patterson SD. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013, 19:1902-1912. 10.1158/1078-0432.CCR-12-1913, 23325582.
7. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762. 10.1016/S1470-2045(10)70130-3, 20619739.
8. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27(35):5924-5930. 10.1200/JCO.2008.21.6796, 19884556.
9. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712. 10.1200/JCO.2008.18.0786, 19001320.
10. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010, 46(11):1997-2009. 10.1016/j.ejca.2010.03.036, 20413299.
11. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29(15):2011-2019. 10.1200/JCO.2010.33.5091, 21502544.
12. Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, Jalaludin B, Segelov E. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 2004, 23(2):617-628. 10.1038/sj.onc.1207059, 14724591.
13. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004, 64(9):3014-3021. 10.1158/0008-5472.CAN-2401-2, 15126336.
14. Li XH, Zheng HC, Takahashi H, Masuda S, Yang XH, Takano Y. PTEN expression and mutation in colorectal carcinomas. Oncol Rep 2009, 22(4):757-764.
15. Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Wakasugi T, Takahashi H, Funahashi H, Sato M, Takeyama H. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol 2008, 8:56. 10.1186/1471-230X-8-56, 2611992, 19036165.
16. Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 2012, 11(2):143-150. 10.1016/j.clcc.2011.12.001, 3350566, 22285706.
17. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009, 27(16):2622-2629. 10.1200/JCO.2008.20.2796, 19398573.
18. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol 2013, 85(1):45-81. 10.1016/j.critrevonc.2012.05.001, 22647972.
19. Ali A, Saluja SS, Hajela K, Mishra PK, Rizvi MA. Mutational and expressional analyses of PTEN gene in colorectal cancer from northern India. Mol Carcinog in press.
20. Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN, Ball RY, Mitrou PN, McTaggart A, Arends MJ. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer 2011, 11:123. 10.1186/1471-2407-11-123, 3080834, 21473780.
21. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 2010, 56(2):229-239. 10.1111/j.1365-2559.2009.03468.x, 20102402.
22. Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 2011, 16(9):1239-1249. 10.1634/theoncologist.2011-0024, 3228174, 21742964.
23. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, Moreno-Rubio J, de Castro CJ, Belda-Iniesta C, Barriuso J, Moreno Garcia V, Diaz E, Burgos E, Gonzalez-Baron M, Feliu J. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. Curr Cancer Drug Targets 2012, 12(2):124-131. 10.2174/156800912799095162, 22229245.
24. Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol 2010, 16(46):5881-5888. 10.3748/wjg.v16.i46.5881, 3001981, 21155011.
25. Lin JK, Lin AJ, Lin CC, Lan YT, Yang SH, Li AF, Chang SC. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. J Surg Oncol 2011, 104(6):661-666. 10.1002/jso.21993, 21671463.
26. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011, 6(1):e15980. 10.1371/journal.pone.0015980, 3024325, 21283802.
27. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4(10):e7287. 10.1371/journal.pone.0007287, 2750753, 19806185.
28. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97(8):1139-1145. 10.1038/sj.bjc.6604009, 2360431, 17940504.
29. Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 2011, 68(4):1045-1055. 10.1007/s00280-011-1586-z, 21340604.
30. Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J, Stone S. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 2011, 19(2):173-183. 10.1097/PAI.0b013e3181f1da13, 20930614.
31. Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichael D, Kostopoulos I, Samantas E, Xanthakis I, Bobos M, Galanidi E, Bai M, Gikonti I, Koukouma A, Kafiri G, Papakostas P, Kalogeras KT, Kosmidis P, Fountzilas G. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer 2008, 8:234. 10.1186/1471-2407-8-234, 2527615, 18700047.
32. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010, 28(19):3191-3198. 10.1200/JCO.2009.27.7723, 20516443.
33. Price TJ, Hardingham JE, Lee CK, Townsend AR, Wrin JW, Wilson K, Weickhardt A, Simes RJ, Murone C, Tebbutt NC. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer medicine 2013, 2(3):277-285. 10.1002/cam4.75, 3699839, 23930204.
34. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, Tsukuda K, Ogasawara Y, Shimizu N. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006, 94(2):247-252. 10.1038/sj.bjc.6602926, 2361109, 16404430.
35. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999, 59(17):4291-4296.
36. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999, 155(4):1253-1260. 10.1016/S0002-9440(10)65227-3, 1867038, 10514407.
37. Abdel-Rahman WM, Katsura K, Rens W, Gorman PA, Sheer D, Bicknell D, Bodmer WF, Arends MJ, Wyllie AH, Edwards PAW. Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci U S A 2001, 98(5):2538-2543. 10.1073/pnas.041603298, 30173, 11226274.
38. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009, 20(1):84-90.
39. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 2010, 16(15):3811-3818. 10.1158/1078-0432.CCR-09-2283, 20554751.
40. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011, 17(20):6563-6573. 10.1158/1078-0432.CCR-11-1244, 3195839, 21878536.
41. Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N, King TA. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 2010, 18(4):371-374. 10.1097/PAI.0b013e3181d50bd5, 2921801, 20216404.
42. Liang L, Wei Y, Ren L, Zhong YS, Xu JM. [A study of the relationship between the mutation of PIK3CA, PTEN and the occurrence of liver metastasis of colorectal cancer: survival analysis]. Zhonghua Wai Ke Za Zhi 2012, 50(11):1007-1010.
43. Jin C, Wang A, Chen J, Liu X, Wang G. Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer. Experimental and therapeutic medicine 2012, 4(4):633-639. 3501400, 23170117.
44. Niemeyer CM, Adler M, Wacker R. Detecting antigens by quantitative immuno-PCR. Nat Protocols 2007, 2(8):1918-1930.